Garner WB, Smith BD, Ludmir EB, et al. Predicting future cancer incidence by age, race, ethnicity, and sex. J Geriatr Oncol. 2023;14:101393.

Article  PubMed  CAS  Google Scholar 

Shelton J, Zotow E, Smith L, et al. 25 year trends in cancer incidence and mortality among adults aged 35–69 years in the UK, 1993–2018: retrospective secondary analysis. BMJ. 2024;384:e076962.

Article  PubMed  PubMed Central  Google Scholar 

Hasan KM. Cannabis unveiled: an exploration of marijuana’s history, active compounds, effects, benefits, and risks on human health. Subst Abuse. 2023;17:11782218231182552.

Google Scholar 

Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42:180–8.

PubMed  PubMed Central  Google Scholar 

Creanga-Murariu I, Filipiuc LE, Cuciureanu M, Tamba B-I, Alexa-Stratulat T. Should oncologists trust cannabinoids? Front Pharmacol. 2023;14:1211506.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Azizoddin DR, Cohn AM, Ulahannan SV, et al. Cannabis use among adults undergoing cancer treatment. Cancer. 2023;129:3498–508.

Article  PubMed  Google Scholar 

Pergam SA, Woodfield MC, Lee CM, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017;123:4488–97.

Article  PubMed  CAS  Google Scholar 

Salz T, Meza AM, Chino F, et al. Cannabis use among recently treated cancer patients: perceptions and experiences. Support Care Cancer. 2023;31:545.

PubMed  PubMed Central  Google Scholar 

Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019;45:644–63.

Article  PubMed  PubMed Central  Google Scholar 

Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guideline. Ann Oncol. 2018;29:iv166-91.

Article  PubMed  CAS  Google Scholar 

Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines☆. ESMO Open. 2021;6:100092.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Braun IM, Bohlke K, Abrams DI, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 2024;42:1575–93.

Article  PubMed  Google Scholar 

Page M, McKenzie J, Bossuyt P, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10: 000142.

Booth A, Clarke M, Dooley G, et al. PROSPERO at one year: an evaluation of its utility. Syst Rev. 2013;2:4.

Article  PubMed  PubMed Central  Google Scholar 

Haddaway NR, Grainger MJ, Gray CT. Citationchaser: A tool for transparent and efficient forward and backward citation chasing in systematic searching. Res Synth Methods. 2022;13:533–45.

Article  PubMed  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

Article  PubMed  PubMed Central  Google Scholar 

Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.

Article  PubMed  Google Scholar 

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

Article  PubMed  Google Scholar 

Pustejovsky JE, Rodgers MA. Testing for funnel plot asymmetry of standardized mean differences. Res Synth Methods. 2019;10:57–71.

Article  PubMed  Google Scholar 

Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: A hands-on guide. Boca Raton: Chapman and Hall/CRC, 2021. https://doi.org/10.1201/9781003107347

Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48:657–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22:2086–93.

Article  PubMed  CAS  Google Scholar 

Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987;79:946–52.

PubMed  CAS  Google Scholar 

Chang AE, Shiling DJ, Stillman RC, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981;47:1746–51.

Article  PubMed  CAS  Google Scholar 

Chang AE, Shiling DJ, Stillman RC, et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med. 1979;91:819–24.

Article  PubMed  CAS  Google Scholar 

Côté M, Trudel M, Wang C, Fortin A. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: A randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol. 2016;125:317–24.

Article  PubMed  Google Scholar 

Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother. 1986;3:39–42.

Article  PubMed  CAS  Google Scholar 

Cunningham D, Bradley CJ, Forrest GJ, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988;24:685–9.

Article  PubMed  CAS  Google Scholar 

Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986;61:502–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Davies BH, Weatherstone RM, Graham JD, Griffiths RD. A pilot study of orally administered Δ(1)-trans-tetrahydrocannabinol in the management of patients undergoing radiotherapy for carcinoma of the bronchus. Br J Clin Pharmacol. 1974;1:301–6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70:656–63.

Article  PubMed  PubMed Central  CAS  Google Scholar